We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+8.06%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.11T
AUM Growth
+$49.3B
Cap. Flow
-$2.91B
Cap. Flow %
-0.26%
Top 10 Hldgs %
27.74%
Holding
3,121
New
186
Increased
817
Reduced
1,825
Closed
148

Top Buys

Rank Stock Value
1
RIVN icon
Rivian
RIVN
+$18.7B
2
AAPL icon
Apple
AAPL
+$5.48B
3
NVDA icon
NVIDIA
NVDA
+$5.33B
4
TSLA icon
Tesla
TSLA
+$4.47B
5
MSFT icon
Microsoft
MSFT
+$2.15B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$4.26B
2
META icon
Meta Platforms (Facebook)
META
+$3.3B
3
MS icon
Morgan Stanley
MS
+$2.82B
4
GPN icon
Global Payments
GPN
+$2.43B
5
PYPL icon
PayPal
PYPL
+$2B

Sector Composition

Rank Sector Weight
1 Technology 27.36%
2 Healthcare 16.09%
3 Consumer Discretionary 15.79%
4 Communication Services 12.38%
5 Financials 10.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BRSL
3001
Brightstar Lottery PLC
BRSL
$2.21B
-8,374
Closed -$220K
IMNM icon
3002
Immunome
IMNM
$3.11B
-10,800
Closed -$263K
IMVT icon
3003
Immunovant
IMVT
$8.78B
-22,680
Closed -$197K
JYNT icon
3004
The Joint Corp
JYNT
$125M
-5,057
Closed -$496K
KIDS icon
3005
OrthoPediatrics
KIDS
$651M
-6,461
Closed -$423K
KLXE icon
3006
KLX Energy Services
KLXE
$34.2M
-10,900
Closed -$52K
KRRO icon
3007
Korro Bio
KRRO
$203M
-479
Closed -$169K
LASR icon
3008
nLIGHT
LASR
$3.06B
-20,483
Closed -$577K
LMAT icon
3009
LeMaitre Vascular
LMAT
$1.88B
-10,014
Closed -$532K
LU icon
3010
Lufax Holding
LU
$1.35B
-2,850
Closed -$80K
MAG
3011
DELISTED
MAG Silver
MAG
-1,793,413
Closed -$29.1M
RJET
3012
Republic Airways Holdings
RJET
$964M
-7,869
Closed -$904K
MNSO icon
3013
MINISO
MNSO
$3.54B
-1,974,756
Closed -$30.1M
MTNB icon
3014
Matinas BioPharma
MTNB
$1.51M
-3,396
Closed -$221K
NATR icon
3015
Nature's Sunshine
NATR
$277M
-206,020
Closed -$3.02M
NERV icon
3016
Minerva Neurosciences
NERV
$186M
-7,038
Closed -$98K
NET icon
3017
PUT
Cloudflare
NET
$115B
-23,200
Closed -$2.61M
PAYS icon
3018
Paysign
PAYS
$739M
-23,500
Closed -$63K
PLCE icon
3019
Children's Place
PLCE
$55.8M
-2,692
Closed -$203K
PRDO icon
3020
Perdoceo Education
PRDO
$1.99B
-2,605,173
Closed -$27.5M
RLMD icon
3021
Relmada Therapeutics
RLMD
$499M
-8,057
Closed -$211K
RYTM icon
3022
Rhythm Pharmaceuticals
RYTM
$7.99B
-16,712
Closed -$218K
SINT icon
3023
SiNtx Technologies
SINT
$11.1M
-5
Closed -$132K
SLDB icon
3024
Solid Biosciences
SLDB
$965M
-272,557
Closed -$9.77M
SNDX icon
3025
Syndax Pharmaceuticals
SNDX
$1.75B
-516,098
Closed -$9.86M

Similar funds

T. Rowe Price Associates's Q4 2021 Portfolio in Review

As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
  • T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
  • T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
  • T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
  • T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
  • T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.